INTRAVITREAL CIDOFOVIR (HPMPC) TREATMENT OF CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME

被引:107
作者
KIRSCH, LS
AREVALO, JF
DELAPAZ, EC
MUNGUIA, D
DECLERCQ, E
FREEMAN, WR
机构
[1] UNIV CALIF SAN DIEGO,SHILEY EYE CTR 0946,DEPT OPHTHALMOL,LA JOLLA,CA 92093
[2] KATHOLIEKE UNIV LEUVEN,REGA INST MED RES,B-3001 LOUVAIN,BELGIUM
关键词
D O I
10.1016/S0161-6420(95)30985-2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The authors previously conducted a pilot, dose-escalating study which suggested that a 20-mu g dose of intravitreal cidofovir (HPMPC) may be safe and effective in treating cytomegalovirus (CMV) retinitis in humans. The purpose of this series is to expand the authors' prior experience with the 20-mu g dose of cidofovir as the sole treatment for CMV retinitis in patients with acquired immune deficiency syndrome. Methods: The study design was an unmasked consecutive case series trial in a single-center institutional retina referral practice. Eligible patients with acquired immune deficiency syndrome had active CMV retinitis in at least one eye and no evidence of extraocular CMV disease. Patients received a 20-mu g cidofovir trans pars plana injection and were treated with concomitant oral probenecid. Retreatments were performed for progression of retinitis as determined by serial fundus photographs judged independently by three observers. The primary outcome was time to retinitis progression determined by Kaplan-Meier analysis. Both globes of one patient who had unilateral retinitis were examined pathologically. Results: There were 37 cidofovir injections in 24 eyes of 17 patients. The median time to retinitis progression after the initial 24 injections was 55 days. The median time to retinitis progression after 8 repeat cidofovir injections was 63 days. There was a significant decrease in intraocular pressure from baseline to both 2 and 4 weeks after injection. A mild to moderate iritis developed in five (20.8%) eyes that responded well to topical medications. Results of histopathologic examination of one treated globe did not show any significant toxic effects. Conclusions: This study demonstrates that prolonged arrest of the progression of CMV retinitis may be obtained with a single 20-mu g cidofovir intravitreal injection. In addition, the effect of the drug appears to be maintained after a second injection. The effects of cidofovir in causing uveitis and a slight lowering of the intraocular pressure require further study.
引用
收藏
页码:533 / 542
页数:10
相关论文
共 33 条
[1]   COMPARATIVE ACTIVITY OF SELECTED ANTIVIRAL COMPOUNDS AGAINST CLINICAL ISOLATES OF HUMAN CYTOMEGALOVIRUS [J].
ANDREI, G ;
SNOECK, R ;
SCHOLS, D ;
GOUBAU, P ;
DESMYTER, J ;
DECLERCQ, E .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (12) :1026-1033
[2]  
[Anonymous], 1992, Control Clin Trials, V13, P22
[3]   EVALUATION OF HPMPC THERAPY FOR PRIMARY AND RECURRENT GENITAL HERPES IN MICE AND GUINEA-PIGS [J].
BRAVO, FJ ;
STANBERRY, LR ;
KIER, AB ;
VOGT, PE ;
KERN, ER .
ANTIVIRAL RESEARCH, 1993, 21 (01) :59-72
[4]  
COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348
[5]   INTRAVENOUS AND INTRAOCULAR GANCICLOVIR FOR CMV RETINITIS IN PATIENTS WITH AIDS OR CHEMOTHERAPEUTIC IMMUNOSUPPRESSION [J].
DAIKOS, GL ;
PULIDO, J ;
KATHPALIA, SB ;
JACKSON, GG .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1988, 72 (07) :521-524
[6]   THERAPEUTIC POTENTIAL OF HPMPC AS AN ANTIVIRAL DRUG [J].
DECLERCQ, E .
REVIEWS IN MEDICAL VIROLOGY, 1993, 3 (02) :85-96
[7]   A NOVEL SELECTIVE BROAD-SPECTRUM ANTI-DNA VIRUS AGENT [J].
DECLERCQ, E ;
HOLY, A ;
ROSENBERG, I ;
SAKUMA, T ;
BALZARINI, J ;
MAUDGAL, PC .
NATURE, 1986, 323 (6087) :464-467
[8]  
DREW WL, 1993, MULTIDISCIPLINARY AP, P287
[9]   NEW VISUAL-ACUITY CHARTS FOR CLINICAL RESEARCH [J].
FERRIS, FL ;
KASSOFF, A ;
BRESNICK, GH ;
BAILEY, I .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1982, 94 (01) :91-96
[10]  
FLORESAGUILAR M, 1993, OPHTHALMOLOGY, V100, P1022